Anticancer agent 284
Anticancer agent 284 exhibits cytotoxicity against osteosarcoma cell line (Hos), non-small cell lung cancer cell line (A549), and colon cancer cell line (HCT-116) . Anticancer agent 284 can impact the pRIPK3 kinase concentration in the A549 (2.97 pg/mL) . Anticancer agent 284 can be used for the study of cancer[1].
Product Specifications
UNSPSC
12352005
Target
RIP kinase
Related Pathways
Apoptosis
Field of Research
Cancer
Smiles
CC1=CC=C(C=C1)S(=O)(N/N=C(C2=CC=C(C=C2)N/C=C3C(N(N=C/3C)C4=CC=CC=C4)=O)\C)=O
Molecular Formula
C26H25N5O3S
Molecular Weight
487.57
References & Citations
[1]Ahmed AA, et al. Multi-step organic synthesis, cytotoxicity, and molecular docking of new N-phenylpyrazolones incorporated with N-benzylthiazole or N-benzyl-4-thiazolone fragments. Sci Rep. 2025 Sep 29;15 (1) :33340.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15288948 1 Vial
Lentiviral human GUCA1B shRNA (UAS) - Lentiviral human GUCA1B shRNA (UAS, RFP) (100)
Sign In for Pricing
View Details 
AE29760HU-01 48 Tests
Human Inositol polyphosphate 5-phosphatase OCRL-1 (OCRL) ELISA Kit
Sign In for Pricing
View Details AE29760HU-02 96 Tests
Human Inositol polyphosphate 5-phosphatase OCRL-1 (OCRL) ELISA Kit
Sign In for Pricing
View Details 